Spleen size (cm below costal margin) 0 (0-16) 3 (0-15) 2 (0-16) Sokal score 0.83 (0.67-1.69) 1.11 (0.69-1.69) 0.76 (0.67-1.59) Euro Score 912.
Patient cohort, demographics and antibody panel
Longitudinally collected samples from a subset of patients enrolled in the Evaluating Nilotinib Efficacy and Safety as First-Line Treatment (ENEST1st) 1 (CAMN107EIC01) clinical trial were evaluated. An overview of patients analysed in the two datasets is shown 
2) Mass cytometry barcoding, staining and gating strategies.
A barcoding scheme was developed in-house for dataset #1 where each of the longitudinally collected patient, or healthy, peripheral blood (PB) samples was assigned, and stained with a single palladium isotope and subsequently pooled (Supplemental Figure 1) . The PB samples from each patient collected before first dose of nilotinib, and after 3 hours, 7 days, and 28 days was stained with Pd 102, 104, 106 or 108, respectively. 
Supplementary Material
For dataset #2, a commercially available kit for barcoding was used (Fluidigm) according to manufacturers instructions 2 . Subsequently for both barcoding approaches, the pool of For samples barcoded with the commercially available barcoding kit (Fluidigm), the single cell debarcoder algorithm was used for sample deconvolution and further doublet removal (https://github.com/nolanlab/single-cell-debarcoder).
Antibody validation for dataset #1
We validated the specificity of the intracellular phospho-specific antibodies by exposing the CML blast phase cell line K562 in vitro to nilotinib (50 and 500 nM, 2 hours), interferon-α (HuINF-α-Le 2000 IU/mL, 15 min) or tert-butyl hydrogen peroxide (TBHP, 400 µM, 1 h). Nilotinib treated K562 cells were lysed and the pSTAT5 Y694, pCRKL Y207 and pBCR Y177 level measured by western blotting (Supplemental Figure 2 -A) .
In addition, the cells were stained with mass-tagged phospho-specific antibodies and changes in signal transduction were measured by mass cytometry and heat mapped as an arcsinh ratio of control and treated cells (Supplemental Figure 2 
Extended antibody validations for dataset #2

Additional cell surface markers
To further increase the immunophenotyping resolution of the myeloid lineage, the antibody panel was extended with a selection of carefully chosen cell surface markers. This panel was then used to investigate the diagnostic PB samples collected from three ENEST1st trial 1 patients (4303-00003, 3101-00011 and 3581_00002) and a single healthy donor PB sample. We performed a data-driven analysis of the generated high dimensional data using the PhenoGraph algorithm 5 Arcsinh ratio was calculated to compute changes in signal transduction, and the scale was adjusted to ±1.5
to improve resolution. C) Histograms show the baseline variation between the cell lines, relative to K562.
In the CML blast phase cell line K562, both dasatinib and nilotinib down-regulated the phosphorylation of pBCR Y177 and pAbl Y245, but also the signalling substrates of Bcr-Abl1; pCRKL Y207 and pSTAT5 Y694. Furthermore indicating antibody specificity, the basal phosphorylation level (in untreated cells) of pBCR Y177, pAbl Y245, pCRKL Y207 and pSTAT5 Y694, interestingly pCREB S133, was clearly elevated in K562 cell line compared to the two other non-CML cell lines (Supplemental Figure 5 -B) .
Supporting data for dataset #2
A second cohort of patients (n=8) Some cellular subsets were identifiable only in some of patients.
We measured the 75 th percentile of each intracellular phosphor-specific target (pBcr Y177, pAbl Y245, pCrKL Y207, pSTAT1 Y701, pSTAT3 Y705, pSTAT5 Y694, pCREB S133, pErk ½ T202/Y204, pS6 S235/36 and pS6 S240/44) in the subsets (Figure 3) . The arcsinh ratio between before treatment initiation and both after 3 hours and 7 days in each population was calculated. The patient cohort (n=8) was divided into two groups based on the BCR-ABL1 IS at 3 and 6 months (best and worst initial responders to nilotinib). The arcsinh ratio between before treatment initiation and both after 3 hours and 7 days is shown for these two groups in Supplemental Figure 6 . This arcsinh ratio data was used to perform the PCA analysis in Figure 3 .
